DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Humalog Mix75 / 25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection (Rdna Origin)) - Published Studies

 
 



Published Studies Related to Humalog Mix75/25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection)

Well-designed clinical trials related to Humalog Mix75/25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection)

Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes. [2010.05]

The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. [2005.12]

Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. [2004.04]

Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. [2003.09]

Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. [2003.03]

Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. [2002.01]

Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. [2000.12]

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. [2000.02]

Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. [1999.03]

Other research related to Humalog Mix75/25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection)

Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. [2010.05]

Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. [2010]

Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance. [2008.01]

Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus. [2008]

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA(1c) and pre- and postprandial blood glucose levels in patients with type 2 diabetes: A multinational, 24-week, randomized, open-label, parallel-group comparison. [2007.11]

Advancing Insulin Therapy in Type 2 Diabetes, Previously Treated with Glargine Plus Oral Agents: Prandial Premixed (Lispro/ILPS) vs. Basal/Bolus (Glargine/Lispro) Therapy. [2007.10.12]

Premixed insulin analogues for the treatment of diabetes mellitus. [2006]

The impact of the timing of Humalog((R)) Mix25trade mark injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. [2005.11.24]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017